Mycophenolic acid is a potent inhibitor of the expression of tumour necrosis factor- and tumour necrosis factor-receptor superfamily costimulatory molecules.

PubWeight™: 0.75‹?›

🔗 View Article (PMC 1782937)

Published in Immunology on May 01, 2003

Authors

Miranda M L Van Rijen1, Herold J Metselaar, Martijn Hommes, Jan N M Ijzermans, Hugo W Tilanus, Jaap Kwekkeboom

Author Affiliations

1: Department of Gastroenterology & Hepatology, Erasmus MC, Rotterdam, the Netherlands.

Articles cited by this

A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature (1998) 12.07

Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature (1996) 6.61

CD27 is required for generation and long-term maintenance of T cell immunity. Nat Immunol (2000) 3.84

Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med (1999) 3.41

4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med (1997) 3.31

OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity (2001) 3.08

Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J Immunol (1998) 2.74

Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection. Proc Natl Acad Sci U S A (1996) 2.40

4-1BB ligand, a member of the TNF family, is important for the generation of antiviral CD8 T cell responses. J Immunol (1999) 1.63

CD40-CD40 ligand interactions are critical in T-B cooperation but not for other anti-viral CD4+ T cell functions. J Exp Med (1996) 1.62

Costimulation of CD28- T lymphocytes by 4-1BB ligand. J Immunol (1997) 1.59

CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand. J Exp Med (1998) 1.54

T cell co-stimulatory molecules other than CD28. Curr Opin Immunol (1999) 1.43

Differential effects of cyclosporine A, methylprednisolone, mycophenolate, and rapamycin on CD154 induction and requirement for NFkappaB: implications for tolerance induction. Transplantation (2000) 1.43

Signaling through OX40 (CD134) breaks peripheral T-cell tolerance. Nat Med (2001) 1.40

Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus. J Immunol (1999) 1.36

Control of lymphocyte function through CD27-CD70 interactions. Semin Immunol (1998) 1.33

mTOR inhibitors: an overview. Liver Transpl (2001) 1.32

Cutting edge: blockade of the CD28/B7 costimulatory pathway inhibits intestinal allograft rejection mediated by CD4+ but not CD8+ T cells. J Immunol (1999) 1.20

Rapamycin induces apoptosis in monocyte- and CD34-derived dendritic cells but not in monocytes and macrophages. Blood (2001) 1.16

CD40-CD40 ligand-independent activation of CD8+ T cells can trigger allograft rejection. J Immunol (2000) 1.15

Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, graft-versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients. J Immunol (2001) 1.14

Immunosuppressive agents in organ transplantation: past, present, and future. Semin Nephrol (2000) 1.14

Blockade of CD134 (OX40)-CD134L interaction ameliorates lethal acute graft-versus-host disease in a murine model of allogeneic bone marrow transplantation. Blood (2000) 1.12

IL-2 and IL-15 regulate CD154 expression on activated CD4 T cells. J Immunol (2000) 1.08

CD137 is expressed by follicular dendritic cells and costimulates B lymphocyte activation in germinal centers. J Leukoc Biol (2002) 1.04

CD70 expression on T-cell subpopulations: study of normal individuals and patients with chronic immune activation. Immunol Lett (1997) 1.02

Skin allograft rejection in CD28-deficient mice. Transplantation (1996) 0.99

Mechanisms of action of mycophenolic acid. Ann N Y Acad Sci (1993) 0.96

CD8+ T cells contribute to the development of transplant arteriosclerosis despite CD154 blockade. Transplantation (2000) 0.95

Flow cytometric quantitation of calcium-dependent and -independent mitogen-stimulation of T cell functions in whole blood: inhibition by immunosuppressive drugs in vitro. J Immunol Methods (2001) 0.90

Pharmacodynamics of immunosuppression by mycophenolic acid: inhibition of both lymphocyte proliferation and activation correlates with pharmacokinetics. J Pharmacol Exp Ther (1999) 0.88

Prolongation of primate cardiac allograft survival by treatment with ANTI-CD40 ligand (CD154) antibody. Transplantation (1999) 0.86

Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range. Transplantation (2002) 0.85

Strong expression of CD134 (OX40), a member of the TNF receptor family, in a T helper 2-type cytokine environment. J Leukoc Biol (1998) 0.83

Pharmacodynamics of mycophenolic acid in heart allograft recipients: correlation of lymphocyte proliferation and activation with pharmacokinetics and graft histology. Transplantation (2000) 0.80

Cyclosporine inhibition of leukocyte calcineurin is much less in whole blood than in culture medium. Transplantation (1996) 0.80

The effect of OX40/OX40L and CD27/CD70 pathways on allogeneic islet graft rejection. Transplant Proc (2001) 0.80

CD154 is expressed during treatment with calcineurin inhibitors after organ transplantation. Transplantation (2002) 0.78

Articles by these authors

Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med (2002) 8.72

Management in patients with liver cirrhosis and an umbilical hernia. Surgery (2007) 4.09

Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells. Proc Natl Acad Sci U S A (2013) 2.99

Verification and unmasking of widely used human esophageal adenocarcinoma cell lines. J Natl Cancer Inst (2010) 2.79

Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg (2007) 2.78

End-to-end versus end-to-side esophagogastrostomy after esophageal cancer resection: a prospective randomized study. Ann Surg (2011) 2.56

Fibrinolysis during liver transplantation is enhanced by using solvent/detergent virus-inactivated plasma (ESDEP). Anesth Analg (2002) 2.41

Cytokine gene polymorphisms and acute liver graft rejection: a meta-analysis. Liver Transpl (2005) 2.21

Protection against renal ischemia-reperfusion injury by ischemic postconditioning. Transplantation (2013) 2.17

Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study. Acta Oncol (2006) 2.16

Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. Lancet (2004) 2.06

Cost effectiveness of laparoscopic versus mini-incision open donor nephrectomy: a randomized study. Transplantation (2007) 2.05

Sternotomy or drainage for a hemopericardium after penetrating trauma: a randomized controlled trial. Ann Surg (2014) 2.03

Hepatocyte-derived microRNAs as serum biomarkers of hepatic injury and rejection after liver transplantation. Liver Transpl (2012) 1.98

Selective decontamination of the digestive tract to prevent postoperative infection: a randomized placebo-controlled trial in liver transplant patients. Crit Care Med (2002) 1.98

A J-shaped subcostal incision reduces the incidence of abdominal wall complications in liver transplantation. Liver Transpl (2008) 1.96

Cure of Barrett's carcinoma by ifosfamide chemotherapy. Eur J Gastroenterol Hepatol (2002) 1.92

Validation of a liver adenoma classification system in a tertiary referral centre: implications for clinical practice. J Hepatol (2010) 1.91

An evaluation of prognostic factors and tumor staging of resected carcinoma of the esophagus. Ann Surg (2007) 1.79

Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg (2004) 1.79

Electrocautery therapy for refractory anastomotic strictures of the esophagus. Gastrointest Endosc (2006) 1.76

Outcome of surgical treatment for early adenocarcinoma of the esophagus or gastro-esophageal junction. Virchows Arch (2005) 1.74

Focal nodular hyperplasia: findings at state-of-the-art MR imaging, US, CT, and pathologic analysis. Radiographics (2004) 1.73

End-stage renal failure and regulatory activities of CD4+CD25bright+FoxP3+ T-cells. Nephrol Dial Transplant (2009) 1.71

Early recurrence after liver resection for colorectal metastases: risk factors, prognosis, and treatment. A LiverMetSurvey-based study of 6,025 patients. Ann Surg Oncol (2013) 1.68

Preoperative assessment of tumor location and station-specific lymph node status in patients with adenocarcinoma of the gastroesophageal junction. World J Surg (2013) 1.64

Is the clinical risk score for patients with colorectal liver metastases still useable in the era of effective neoadjuvant chemotherapy? Ann Surg Oncol (2011) 1.63

Preoperative fasting protects mice against hepatic ischemia/reperfusion injury: mechanisms and effects on liver regeneration. Liver Transpl (2011) 1.59

Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age. Liver Transpl (2010) 1.59

Glucose supplementation does not interfere with fasting-induced protection against renal ischemia/reperfusion injury in mice. Transplantation (2011) 1.57

Ingestion of acid and alkaline agents: outcome and prognostic value of early upper endoscopy. Gastrointest Endosc (2004) 1.57

ABO-incompatible kidney transplant recipients have a higher bleeding risk after antigen-specific immunoadsorption. Transpl Int (2014) 1.53

Organ donations and unused potential donations in traumatic brain injury, subarachnoid haemorrhage and intracerebral haemorrhage. Intensive Care Med (2006) 1.53

Physical fitness, fatigue, and quality of life after liver transplantation. Eur J Appl Physiol (2007) 1.52

Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transpl (2002) 1.51

Conversion from calcineurin inhibitor to mycophenolate mofetil-based immunosuppression changes the frequency and phenotype of CD4+FOXP3+ regulatory T cells. Transplantation (2009) 1.50

Intrahepatic detection of FOXP3 gene expression after liver transplantation using minimally invasive aspiration biopsy. Transplantation (2007) 1.49

Validation of a nomogram predicting complications after esophagectomy for cancer. Ann Thorac Surg (2010) 1.47

Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. Hepatology (2004) 1.46

Cancer inflammation and inflammatory biomarkers: can neutrophil, lymphocyte, and platelet counts represent the complexity of the immune system? Transpl Int (2014) 1.45

Barrett's oesophageal adenocarcinoma encompasses tumour-initiating cells that do not express common cancer stem cell markers. J Pathol (2010) 1.44

Altruistic living kidney donation challenges psychosocial research and policy: a response to previous articles. Transplantation (2005) 1.44

The β-human chorionic gonadotropin-related peptide LQGV reduces mortality and inflammation in a murine polymicrobial sepsis model. Crit Care Med (2011) 1.42

Ultrasound, computed tomography, or the combination for the detection of supraclavicular lymph nodes in patients with esophageal or gastric cardia cancer: a comparative study. J Surg Oncol (2007) 1.42

The sentinel node concept in adenocarcinomas of the distal esophagus and gastroesophageal junction. J Thorac Cardiovasc Surg (2009) 1.39

High-dose intravenous immunoglobulin does not reduce the numbers of circulating CD14(+)CD16(++) monocytes in patients with inflammatory disorders. Clin Immunol (2012) 1.39

Surgical mortality in patients with esophageal cancer: development and validation of a simple risk score. J Clin Oncol (2006) 1.39

Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol (2008) 1.35

Activated tumor-infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer. Hepatology (2012) 1.33

The molecular biology of esophageal adenocarcinoma. J Surg Oncol (2005) 1.32

Comparison of the 6th and 7th Editions of the UICC-AJCC TNM Classification for Esophageal Cancer. Ann Surg Oncol (2012) 1.29

Hepatocellular adenomas: correlation of MR imaging findings with pathologic subtype classification. Radiology (2011) 1.29

Mistaken identity of widely used esophageal adenocarcinoma cell line TE-7. Cancer Res (2007) 1.27

Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: long-term results of a randomized controlled trial. BMC Cancer (2011) 1.27

Abundant numbers of regulatory T cells localize to the liver of chronic hepatitis C infected patients and limit the extent of fibrosis. J Hepatol (2009) 1.24

Simultaneous targeting of HCV replication and viral binding with a single lentiviral vector containing multiple RNA interference expression cassettes. Mol Ther (2006) 1.24

Donor-derived mesenchymal stem cells suppress alloreactivity of kidney transplant patients. Transplantation (2009) 1.22

Hepatic cell-to-cell transmission of small silencing RNA can extend the therapeutic reach of RNA interference (RNAi). Gut (2011) 1.21

Live donor nephrectomy: a review of evidence for surgical techniques. Transpl Int (2009) 1.17

The choice of anatomical site for islet transplantation. Cell Transplant (2008) 1.17

KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. Int J Cancer (2013) 1.16

Human adipose tissue-derived mesenchymal stem cells induce explosive T-cell proliferation. Stem Cells Dev (2010) 1.16

Effects of Hypoxia on the Immunomodulatory Properties of Adipose Tissue-Derived Mesenchymal Stem cells. Front Immunol (2013) 1.11

Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha. Gastroenterology (2006) 1.10

Complex vascular anatomy in live kidney donation: imaging and consequences for clinical outcome. Transplantation (2008) 1.09

Advancement of mesenchymal stem cell therapy in solid organ transplantation (MISOT). Transplantation (2010) 1.07

Relaparotomy following complications of feeding jejunostomy in esophageal surgery. Dig Surg (2004) 1.07

Increased incidence of adenocarcinomas at the gastro-oesophageal junction in Dutch males since the 1990s. Eur J Gastroenterol Hepatol (2002) 1.05

The effect of nitroglycerin on microvascular perfusion and oxygenation during gastric tube reconstruction. Anesth Analg (2005) 1.03

Fatty acid composition of plasma lipids in patients with pancreatic, lung and oesophageal cancer in comparison with healthy subjects. Clin Nutr (2002) 1.03

Immunohistochemical evaluation of a panel of tumor cell markers during malignant progression in Barrett esophagus. Am J Clin Pathol (2008) 1.02

Excellent survival after liver transplantation for isolated polycystic liver disease: an European Liver Transplant Registry study. Transpl Int (2011) 1.02

Epidemiology and management of chronic hepatitis E infection in solid organ transplantation: a comprehensive literature review. Rev Med Virol (2013) 1.01

Low circulating regulatory T-cell levels after acute rejection in liver transplantation. Liver Transpl (2006) 1.01

The effect of rabbit anti-thymocyte globulin induction therapy on regulatory T cells in kidney transplant patients. Nephrol Dial Transplant (2009) 1.01

Outcome of microscopic incomplete resection (R1) of colorectal liver metastases in the era of neoadjuvant chemotherapy. Ann Surg Oncol (2011) 1.01

Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C Virus infection in vitro and in vivo. Hepatology (2012) 1.00

Delay in diagnostic workup and treatment of esophageal cancer. J Gastrointest Surg (2009) 1.00